Full Name
Mr. Kent Barnes
Job Title
Vice President and Franchise Head
Practice/Company Name
SeaGen
Speaker Bio
Kent began his career in the pharmaceutical industry in 1996, soon after graduating from the University of Oregon. After a few years of selling primary care products in the hypertension, diabetes, cholesterol and CNS space, Kent was personally drawn to the oncology space where he sold chemotherapies like Taxol, Carboplatin, Ifosfamide, & etoposide for Bristol Myers Squibb … and then epirubicin, exemestane, & irinotecan at Pharmacia Oncology. Kent moved into marketing for irinotecan right before Pfizer’s purchase of Pharmacia, which led him to Genentech. Kent held ~10 positions of escalating responsibilities in his many years at Genentech, which included marketing, sales and pipeline team leadership assignments. Driven by a desire to experience a smaller & more entrepreneurial-staged organization, he joined Medivation (prior to another Pfizer acquisition) as Head of US Marketing for Xtandi and Commercial Pipeline Development. From there he joined Clovis Oncology as VP of Global Marketing & Commercial Analytics and built the teams & launch plans for their small oncology portfolio. After 3 years, and the unpleasant experience of having 2 of the 3 drugs in the portfolio fail in clinical trials, he took a position at Halozyme Therapeutics as VP of Commercial and built out their commercial organization to ready itself for the launch of their pancreatic cancer drug (which ultimately failed in Phase III, as most drugs do in this cancer). Kent joined Seagen in 2018, and serves as a US Commercial Franchise Head. Kent and his wife Lisa, have 3 adult children and they just finished building a home in Oregon’s wine country.
Kent Barnes